Spago Nanomedical has appointed lead compound in the Tumorad project and is now proceeding development into pre-clinical proof-of-concept validation in tumor models.
”Nomination of lead compound is an important step marking that we now hold a material that fulfills our strict requirements on pharmacokinetic and chemical properties for selective accumulation in solid tumors, as well as clinical use,” says Spago Nanomedical CSO Oskar Axelsson.
The immediate aim is to initiate preclinical proof of concept studies in suitable tumor models.
The design of the lead compound particle also opens further possibilities to increase the patent protection for Tumorad. As of before, Spago Nanomedical holds approved patents comprising product protection for Tumorad in strategically important markets for radionuclide therapies until at least 2035.
Photo of Oskar Axelsson: Emil Aaltonen